Trials / Terminated
TerminatedNCT02937675
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Effector Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508). The study will evaluate oral daily administration of Tomivosertib (eFT-508). Treatment and study subject evaluation will be performed in 21-day cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tomivosertib (eFT-508) | eFT508 |
Timeline
- Start date
- 2017-02-08
- Primary completion
- 2018-11-12
- Completion
- 2019-04-04
- First posted
- 2016-10-18
- Last updated
- 2020-11-02
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02937675. Inclusion in this directory is not an endorsement.